Suppr超能文献

贲门失弛缓症的治疗

Treatment of Achalasia.

作者信息

Kaufman Jedediah A, Oelschlager Brant K

机构信息

Department of Surgery, University of Washington, 1959 NE Pacific St., Box 356410, Seattle, WA 98195-6410, USA.

出版信息

Curr Treat Options Gastroenterol. 2005 Feb;8(1):59-69. doi: 10.1007/s11938-005-0052-6.

Abstract

Achalasia is a primary motility disorder of the esophagus that causes dysphagia. Normal esophageal motility and lower esophageal sphincter (LES) function can not be restored; thus treatment is directed at decreasing the pressure or disrupting the muscle fibers of the LES to allow passage of ingested material. Effective therapy for achalasia can be broadly characterized as surgery based or endoscopy based. Medications (calcium channel blockers and nitrate derivatives) do not provide adequate relief of dysphagia and have substantial side effects, and thus are rarely used as long-term therapy. Botulinum toxin injection, a recently introduced endoscopic therapy, enjoyed much enthusiasm initially but was shown to have only transient effect and is now recommended only for poor operative candidates. The mainstay of therapy remains endoscopic dilation or laparoscopic esophagomyotomy (LEM) combined with an antireflux procedure. We have found that patients who can tolerate a laparoscopic abdominal surgery are best served with an LEM and Toupet (270 degrees ) posterior fundoplication. This provides good or excellent relief of dysphagia in 90% to 95% of patients with very little morbidity.

摘要

贲门失弛缓症是一种导致吞咽困难的原发性食管动力障碍性疾病。正常的食管动力和食管下括约肌(LES)功能无法恢复;因此,治疗旨在降低LES的压力或破坏其肌纤维,以使摄入的物质能够通过。贲门失弛缓症的有效治疗方法大致可分为基于手术或基于内镜的治疗。药物(钙通道阻滞剂和硝酸盐衍生物)不能充分缓解吞咽困难,且有严重的副作用,因此很少用作长期治疗。肉毒杆菌毒素注射是一种最近引入的内镜治疗方法,最初备受青睐,但后来发现其效果只是暂时的,现在仅推荐用于手术耐受性差的患者。治疗的主要方法仍然是内镜扩张或腹腔镜食管肌层切开术(LEM)联合抗反流手术。我们发现,能够耐受腹腔镜腹部手术的患者,采用LEM和Toupet(270度)后壁胃底折叠术效果最佳。这能使90%至95%的患者吞咽困难得到良好或极佳的缓解,且发病率极低。

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验